FDA Recalls Thyroid Pills Over ‘Superpotency’: What Patients Need To Know
The FDA has issued a Class I recall for a specific lot of thyroid tablets due to potential superpotency, which may expose patients to excessive thyroid hormone. Patients should check their medication and consult healthcare providers.
What Happened?
The FDA has issued a Class I recall for a specific lot of thyroid tablets due to potential superpotency, which may expose patients to excessive thyroid hormone. Patients should check their medication and consult healthcare providers.
AI Quick Summary
The FDA recalls a specific lot of thyroid tablets due to potential superpotency, urging patients to consult healthcare providers.
Key points
- The FDA recalled a specific lot of Thyroid Tablets, USP 30 mg due to potential superpotency.
- The recall is classified as Class I, indicating a reasonable probability of serious health consequences.
- Patients should check for lot number 504950 and consult healthcare providers before making any changes.
- Excessive thyroid hormone can lead to symptoms like weight loss, fatigue, and heart issues.
- The affected lot was distributed in the US between January 31 and September 30, 2025.
Key insights
- Patients need to verify their medication lot number to avoid health risks.
- Older adults and pregnant women are particularly at risk from excessive thyroid hormone exposure.
- Healthcare providers should guide patients on managing thyroid medication changes.
Why it matters
This recall is crucial as excessive thyroid hormone can lead to serious health issues, particularly for vulnerable populations.
Entities
Source
Times Now
